Which cancers is most effective with Bezotivan?

Belzutifan is a targeted drug with an innovative mechanism. Its development has successfully filled the gap in the past that lacked specific treatments for certain "refractory cancers". As the world's first HIF-2α inhibitor approved for marketing, besotivan's most significant therapeutic effect is currently focused on tumors related to Von Hippel-Lindau syndrome (Von Hippel-Lindau, VHL), especially in the field of VHL-related renal cell carcinoma (RCC).

Renal cell carcinoma, especially the type driven byVHL mutations, has always been a difficult disease category to treat with traditional therapies. In the past, patients mostly relied on repeated surgical resection of lesions or received non-specific targeted therapy. However, due to different mechanisms, the efficacy was often limited. By precisely inhibiting the key HIF-2α protein in the hypoxia-inducible factor (HIF) pathway, Bestivan blocks the ability of tumor cells to adapt to a hypoxic environment from the source. This mechanism is particularly critical in tumors caused by VHL mutations, so it is particularly effective in the treatment of this type of renal cancer. It can even delay tumor progression and reduce dependence on surgery.

In addition to renal cell carcinoma, bezutivan has also shown potential inVHL-related central nervous system hemangioblastoma (CNS hemangioblastoma) and pancreatic neuroendocrine tumors (pNET). These tumors often lack effective drug options in conventional treatment due to their anatomic location or insensitivity to chemoradiotherapy. Through systemic oral administration, bestivan not only has the ability to penetrate the blood-brain barrier, but can also form a synchronized effect on multiple lesions, bringing strong disease control.

In actual use, besotivan is not “one drug suitable for all cancer types”. Its efficacy is highly dependent on whether the tumor is dominated by VHL mutations. Therefore, for non-VHL-related tumors, there is currently a lack of sufficient evidence to prove the efficacy of besetifan.

Reference materials:https://www.welireg.com/